K C Smith1, A D Paltiel2, H Y Yang3, J E Collins4, J N Katz5, E Losina6. 1. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: ksmith81@bwh.harvard.edu. 2. Yale School of Public Health, Yale School of Management, New Haven, CT, USA. Electronic address: david.paltiel@yale.edu. 3. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: hyang29@bwh.harvard.edu. 4. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: jcollins13@bwh.harvard.edu. 5. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: jnkatz@bwh.harvard.edu. 6. Orthopaedic and Arthritis Center for Outcomes Research (OrACORe), Policy and Innovation eValuation in Orthopaedic Treatments (PIVOT) Research Center, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Boston University School of Public Health, Boston, MA, USA. Electronic address: elosina@partners.org.
Abstract
OBJECTIVE: We evaluated the cost-effectiveness of Telephonic Health Coaching and Financial Incentives (THC + FI) to promote physical activity in total knee replacement recipients. DESIGN: We used the Osteoarthritis Policy Model, a computer simulation of knee osteoarthritis, to evaluate the cost-effectiveness of THC + FI compared to usual care. We derived transition probabilities, utilities, and costs from trial data. We conducted lifetime analyses from the healthcare perspective and discounted all cost-effectiveness outcomes by 3% annually. The primary outcome was the Incremental Cost-Effectiveness Ratio (ICER), defined as the ratio of the differences in costs and Quality-Adjusted Life Years (QALYs) between strategies. We considered ICERs <$100,000/QALY to be cost-effective. We conducted one-way sensitivity analyses that varied parameters across their 95% confidence intervals (CI) and limited the efficacy of THC + FI to 1 year or to 9 months. We also conducted a probabilistic sensitivity analysis (PSA), simultaneously varying cost, utilities, and transition probabilities. RESULTS: THC + FI had an ICER of $57,200/QALY in the base case and an ICER below $100,000/QALY in most deterministic sensitivity analyses. THC + FI cost-effectiveness depended on assumptions about long-term efficacy; when efficacy was limited to 1 year or to 9 months, the ICER was $93,300/QALY or $121,800/QALY, respectively. In the PSA, THC + FI had an ICER below $100,000/QALY in 70% of iterations. CONCLUSIONS: Based on currently available information, THC + FI might be a cost-effective alternative to usual care. However, the uncertainty surrounding this choice is considerable, and further research to reduce this uncertainty may be economically justified.
OBJECTIVE: We evaluated the cost-effectiveness of Telephonic Health Coaching and Financial Incentives (THC + FI) to promote physical activity in total knee replacement recipients. DESIGN: We used the Osteoarthritis Policy Model, a computer simulation of knee osteoarthritis, to evaluate the cost-effectiveness of THC + FI compared to usual care. We derived transition probabilities, utilities, and costs from trial data. We conducted lifetime analyses from the healthcare perspective and discounted all cost-effectiveness outcomes by 3% annually. The primary outcome was the Incremental Cost-Effectiveness Ratio (ICER), defined as the ratio of the differences in costs and Quality-Adjusted Life Years (QALYs) between strategies. We considered ICERs <$100,000/QALY to be cost-effective. We conducted one-way sensitivity analyses that varied parameters across their 95% confidence intervals (CI) and limited the efficacy of THC + FI to 1 year or to 9 months. We also conducted a probabilistic sensitivity analysis (PSA), simultaneously varying cost, utilities, and transition probabilities. RESULTS:THC + FI had an ICER of $57,200/QALY in the base case and an ICER below $100,000/QALY in most deterministic sensitivity analyses. THC + FI cost-effectiveness depended on assumptions about long-term efficacy; when efficacy was limited to 1 year or to 9 months, the ICER was $93,300/QALY or $121,800/QALY, respectively. In the PSA, THC + FI had an ICER below $100,000/QALY in 70% of iterations. CONCLUSIONS: Based on currently available information, THC + FI might be a cost-effective alternative to usual care. However, the uncertainty surrounding this choice is considerable, and further research to reduce this uncertainty may be economically justified.
Authors: Larissa Roux; Michael Pratt; Tammy O Tengs; Michelle M Yore; Teri L Yanagawa; Jill Van Den Bos; Candace Rutt; Ross C Brownson; Kenneth E Powell; Gregory Heath; Harold W Kohl; Steven Teutsch; John Cawley; I-Min Lee; Linda West; David M Buchner Journal: Am J Prev Med Date: 2008-12 Impact factor: 5.043
Authors: Sylvia E Furner; Jennifer M Hootman; Charles G Helmick; Julie Bolen; Matthew M Zack Journal: Arthritis Care Res (Hoboken) Date: 2011-06 Impact factor: 4.794
Authors: Elena Losina; Jamie E Collins; Bhushan R Deshpande; Savannah R Smith; Griffin L Michl; Ilana M Usiskin; Kristina M Klara; Amelia R Winter; Heidi Y Yang; Faith Selzer; Jeffrey N Katz Journal: Arthritis Care Res (Hoboken) Date: 2018-04-12 Impact factor: 4.794
Authors: Elena Losina; Rochelle P Walensky; William M Reichmann; Holly L Holt; Hanna Gerlovin; Daniel H Solomon; Joanne M Jordan; David J Hunter; Lisa G Suter; Alexander M Weinstein; A David Paltiel; Jeffrey N Katz Journal: Ann Intern Med Date: 2011-02-15 Impact factor: 25.391
Authors: J N Katz; S R Smith; J E Collins; D H Solomon; J M Jordan; D J Hunter; L G Suter; E Yelin; A D Paltiel; E Losina Journal: Osteoarthritis Cartilage Date: 2015-10-23 Impact factor: 6.576
Authors: Nana K Anokye; Paul Trueman; Colin Green; Toby G Pavey; Melvyn Hillsdon; Rod S Taylor Journal: BMC Public Health Date: 2011-12-26 Impact factor: 3.295
Authors: Gregory C Pope; John Kautter; Randall P Ellis; Arlene S Ash; John Z Ayanian; Lisa I Lezzoni; Melvin J Ingber; Jesse M Levy; John Robst Journal: Health Care Financ Rev Date: 2004
Authors: Emma E Williams; Jeffrey N Katz; Valia P Leifer; Jamie E Collins; Tuhina Neogi; Lisa G Suter; Bruce Levy; Alexander Farid; Clare E Safran-Norton; A David Paltiel; Elena Losina Journal: ACR Open Rheumatol Date: 2022-07-21
Authors: Mark G Pritchard; Jacqueline Murphy; Lok Cheng; Roshni Janarthanan; Andrew Judge; Jose Leal Journal: BMJ Open Date: 2020-01-15 Impact factor: 2.692
Authors: J K Sullivan; J Huizinga; R R Edwards; D J Hunter; T Neogi; E Yelin; J N Katz; E Losina Journal: Osteoarthritis Cartilage Date: 2020-11-07 Impact factor: 6.576